|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
Á¦ ¸ñ |
CYVRNivKQguOsv |
|
ÀÌ ¸§ |
Alexandra |
³¯ Â¥ |
2018/06/28 |
Á¶ ȸ |
4 |
|
Insufficient funds diabeteshealth.com The new drugs are born out of a better understanding of the molecular changes that fuel cancer growth. For example, an estimated 50 to 60 percent of melanoma patients have a specific genetic mutation. Zelboraf and Tafinlar target these people. By testing such treatments only on people with a specific mutation, researchers can work out more quickly, and with fewer patients, if a treatment is effective.
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|